The treatment of multiple myeloma (MM) continues to evolve rapidly with arrival of multiple
new drugs, and emerging data from randomized trials to guide therapy. Along the disease …

Disease overview Multiple myeloma accounts for approximately 10% of hematologic
malignancies. Diagnosis The diagnosis requires≥ 10% clonal bone marrow plasma cells or …

Abstract Disease Overview Multiple myeloma accounts for approximately 10% of
hematologic malignancies. Diagnosis The diagnosis requires≥ 10% clonal bone marrow …

Hematologic malignancies are among the most common cancers, and understanding their
incidence and death is crucial for targeting prevention, clinical practice improvement, and …

Smoldering multiple myeloma (SMM) is an asymptomatic precursor state of multiple
myeloma (MM). Recently, MM was redefined to include biomarkers predicting a high risk of …

New approaches to stratify multiple myeloma patients based on prognosis and therapeutic
decision-making, or prediction, are needed since patients are currently managed in a similar …

Multiple myeloma is a malignant neoplasm of plasma cells that accumulate in bone marrow,
leading to bone destruction and marrow failure. This manuscript discusses the management …

Smoldering multiple myeloma (SMM) is an asymptomatic precursor to multiple myeloma.
Here we define the epidemiological characteristics of SMM in the general population in …

Over the past 20 years, the regulatory approval of several novel agents to treat multiple
myeloma (MM) has prolonged median patient survival from 3 to 8-10 years. Increased …

Background Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the
treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high …